Ampliphi restates financial statements

Ampliphi Biosciences (APHB -5.2%) reports that its financial statements for the period ending September 30,2013 can no longer be relied upon.

The Company's treatment of the non-cash impact of its Series B Preferred Stock, certain promissory notes and certain warrants issued in June and July 2013 should have accounted for them as derivative instruments because they contain anti-dilution protections. Post-issue value fluctuations should then be recorded as non-cash income or expense.

The firm's 2013 10-K will include a discussion of material weaknesses in its internal controls over financial reporting.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs